ClinicalTrials.gg
TerminatedNCT05225558Updated May 6, 2025Results posted

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

A Phase 2 interventional study of Delpazolid and Vancomycin in MRSA Bacteremia, sponsored by LigaChem Biosciences, Inc.. Terminated at 6 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Primary conditionBacteremiaRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bacteremia
Why
  1. The study's listed conditions name Bacteremia, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by LigaChem Biosciences, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Early termination; Difficulties in enrolling subjects due to the decrease in patients with MRSA bacteremia

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.

Read the detailed description

The mortality from S aureus bacteremia is higher for MRSA than for methicillin-susceptible S aureus (MSSA), typically at 20% to 25%.

The current standard therapy for MRSA bacteremia is Vancomycin. Vancomycin has many shortcomings, including poor tissue penetration and slow killing time. Vancomycin has reduced efficacy against MRSA and tended to increase the MIC level (called MIC creep). Addition of Delpazolid to Vancomycin could improve the known drawbacks of Vancomycin alone.

02

Conditions studied

  • MRSA Bacteremia

Browse trials for

Keywords

  • MRSA
  • Staphylococcus aureus bacteremia
  • SAB
  • bloodstream infection
  • BSI
  • Bacteremia
03

In context

Bacteremia Reclassified

298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.

This study's enrollment of 40 is below the median of 156 across 156 interventional studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Compared within Bacteremia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥19 years of age on the date of written consent
  • Subject who has confirmed positive MRSA at least one set of blood cultures within 72 hours prior to randomization OR, Subject who has confirmed positive MRSA at least one set of blood culture whthin 96 hours prior to randomization and treated with vancomycin at least 72 hours prior to randomization
  • Subject who has clinical symptoms or signs of MRSA bacteremia according to the judgment of the investigator
  • Subject who voluntarily decides to participate in this clinical trial after being explained fully, and agrees in writing to implement the clinical trial compliance matters

Exclusion criteria

Exclusion Criteria:

  • Subject with polymicrobial bacteremia or infections including Gram-negative strain
  • Subject undergoing or in need of treatment with antiviral or antifungal drugs
  • Subject who has received treatment for MRSA bacteremia within 3 months of screening (Subjects who have "re-infection" by investigator's judgement may participant in the study.)
  • Subject who has been administered effective antibiotics against MRSA (Vancomycin, etc.) for more than 96 hours prior to the first product administration. (However, antibiotics effective for MRSA such as vancomycin are allowed to be administered for less than 72 hours.)
  • Septic shock patients
  • Subject who has to vancomycin or linezolid
  • Subject who has a history of hypersensitivity to peptide-based antibiotics and aminoglycoside-based antibiotics
  • Subject who is receiving a MAO inhibitor(MAOI) or has received MAOI within 14 days of the first investigational drug administration
  • Subject taking serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptan), meperidine, or buspirone
  • Subject with severely decreased immunity (Severe neutropenia (ANC \<0.5×10\^9/L) etc.)
  • Subject who is expected to die within 2 days due to serious complications of MRSA bacteremia based on the judgment of the investigator
  • (BMI) ≥35 kg/m2
  • Subject who is unable to administer drugs orally
  • Pregnant or lactating female, female or male with who disagrees with the use of appropriate methods during the study and up to 14 days after the last dose of the investigator product
  • Subject who has received other clinical trial drugs within 30 days of screening
  • Subject who is not suitable for participation in this clinical trial according to the medical findings of investigators
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Combination therapy - Vancomycin (IV) plus Delpazolid (PO)

    Vancomycin: IV infusion per 2020 IDSA guideline * Intravenous Vancomycin dosed as per 2020 IDSA guideline * Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion were recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. * Depending on the investigator's judgment, it was allowed to change to Daptomycin after at least one week of administration of Vancomycin, and also it was allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of Vancomycin (including Daptomycin). Delpazolid: 800 mg, BID, PO

    Drug: Delpazolid · Drug: Vancomycin

  • Placebo comparator
    Monotherapy - Vancomycin (IV) plus Placebo of Delpazolid (PO)

    Vancomycin: IV infusion per 2020 IDSA guideline * Intravenous Vancomycin dosed as per 2020 IDSA guideline * Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion were recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. * Depending on the investigator's judgment, it was allowed to change to Daptomycin after at least one week of administration of Vancomycin, and also it was allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of Vancomycin (including Daptomycin). Placebo of Delpazolid: BID, PO

    Drug: Vancomycin · Drug: Placebo of Delpazolid

Interventions

  • BID, PO

    Also known as: LCB01-0371

  • IV infusion per 2020 IDSA guideline

  • DrugPlacebo of Delpazolid

    BID, PO

    Also known as: Placebo of LCB01-0371

06

What researchers measure

Primary outcomes

  1. Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_FAS

    * 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

    Time frame: at Day 14

  2. Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_PPS

    * 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

    Time frame: at Day 14

Secondary outcomes

  1. Overall Cure Rate by End of Treatment (EOT)_FAS

    * 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

    Time frame: Day 7 visit and EOT (up to 6 weeks) visit

  2. Overall Cure Rate by End of Treatment (EOT)_PPS

    * 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

    Time frame: Day 7 visit and EOT (up to 6 weeks) visit

  3. Mortality From MRSA Bacteremia by EOT_FAS

    * Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100

    Time frame: During the treatment period (from the first administration to EOT (up to 6 weeks))

  4. Mortality From MRSA Bacteremia by EOT_PPS

    * Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100

    Time frame: During the treatment period (from the first administration to EOT (up to 6 weeks))

  5. Relapse Rate of MRSA bacteremia_FAS

    * Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100

    Time frame: from the first administration to TOC (4 weeks after EOT)

  6. Relapse Rate of MRSA bacteremia_PPS

    * Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100

    Time frame: from the first administration to TOC (4 weeks after EOT)

  7. Clearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_FAS

    * Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100

    Time frame: Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)

  8. Clearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_PPS

    * Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100

    Time frame: Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)

  9. Persistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_FAS

    * Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100

    Time frame: Day 3, Day 5, Day 7, Day 14

  10. Persistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_PPS

    * Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100

    Time frame: Day 3, Day 5, Day 7, Day 14

  11. Time to Clearance of MRSA bacteremia_FAS

    If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.

    Time frame: by EOT (up to 6 weeks)

  12. Time to Clearance of MRSA bacteremia_PPS

    If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.

    Time frame: by EOT (up to 6 weeks)

Other outcomes

  1. Vancomycin MIC Level

    Vancomycin minimum inhibitory concentration (MIC) levels

    Time frame: at Screening visit (baseline)

  2. Delpazolid MIC Levels

    Delpazolid minimum inhibitory concentration (MIC) level by broth microdilution (BMD)

    Time frame: Screening (Baseline), Day 14, EOT

  3. Pharmacokinetics (PK) parameters_AUC,ss

    Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (AUC,ss: Area under the concentration-time curve at steady state)

    Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.

  4. Pharmacokinetics (PK) parameters_Cmax,ss

    Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmax,ss: Maximum concentration of drug at steady state)

    Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.

  5. Pharmacokinetics (PK) parameters_Cmin,ss

    Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmin,ss: Minimum concentration of drug at steady state)

    Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.

  6. Pharmacokinetics (PK) parameters_Tmax,ss

    Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Tmax,ss: Time to reach Cmax at steady state)

    Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.

  7. Pharmacokinetics (PK) parameters_t1/2β

    Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (t1/2β : Terminal elimination half-life)

    Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.

  8. Pharmacokinetics (PK) parameters_MRT,ss

    Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (MRT,ss: Mean residence time at steady state)

    Time frame: Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.

07

Results

Posted May 6, 2025

Participant flow

This study was initiated on 26 Apr 2022 (first signed informed consent) with the date of last participant who completed last study visit on 18 Mar 2024. A total of 45 participants were screened. Of these, 40 participants were randomized to 1 of 2 arms. The remaining 5 participants were considered to have been screen failures.

Participant flow — Overall Study
MilestoneCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Started2020
Safety set1820
Completed1013
Not completed107
Withdrew: Withdrawal by subject43
Withdrew: Adverse event10
Withdrew: If the following treatment failure criteria are met during treatment period12
Withdrew: When investigators decide that the subject should stop participating in the trial for other reasons42

Outcome measures

PrimaryOverall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_FAS

* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

Time frame:
at Day 14
Reported as:
Count of participants · Participants
Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_FAS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_FAS910
PrimaryOverall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_PPS

* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

Time frame:
at Day 14
Reported as:
Count of participants · Participants
Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_PPS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Overall Cure Rate at Day 14 After the Start of Treatment (Composite Response Rate: Clinical Improvement Plus Clearance of Bacteremia)_PPS99
SecondaryOverall Cure Rate by End of Treatment (EOT)_FAS

* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

Time frame:
Day 7 visit and EOT (up to 6 weeks) visit
Reported as:
Count of participants · Participants
Overall Cure Rate by End of Treatment (EOT)_FAS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Day 776
End of Treatment1214
SecondaryOverall Cure Rate by End of Treatment (EOT)_PPS

* 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests (clearance of bacteremia). If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. * Composite Response rate = (number of participants showing overall cure at Day 14/number of participants in each treatment group) x 100

Time frame:
Day 7 visit and EOT (up to 6 weeks) visit
Reported as:
Count of participants · Participants
Overall Cure Rate by End of Treatment (EOT)_PPS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Day 765
End of Treatment1012
SecondaryMortality From MRSA Bacteremia by EOT_FAS

* Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100

Time frame:
During the treatment period (from the first administration to EOT (up to 6 weeks))
Reported as:
Count of participants · Participants
Mortality From MRSA Bacteremia by EOT_FAS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Overall death01
Death from MRSA bacteremia00
SecondaryMortality From MRSA Bacteremia by EOT_PPS

* Proportion of participants who died due to MRSA bacteremia * Overall mortality = (number of participants who died/number of participants in each treatment group) x 100

Time frame:
During the treatment period (from the first administration to EOT (up to 6 weeks))
Reported as:
Count of participants · Participants
Mortality From MRSA Bacteremia by EOT_PPS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Overall death01
Death from MRSA bacteremia00
SecondaryRelapse Rate of MRSA bacteremia_FAS

* Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100

Time frame:
from the first administration to TOC (4 weeks after EOT)
Reported as:
Count of participants · Participants
Relapse Rate of MRSA bacteremia_FAS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Relapse Rate of MRSA bacteremia_FAS21
SecondaryRelapse Rate of MRSA bacteremia_PPS

* Defined as a positive blood culture to MRSA when previous ones were negative * Relapse rate of MRSA bacteremia = (number of participants with Relapse of MRSA bacteremia after clearance of MRSA bacteremia until TOC visit/number of participants with clearance of MRSA bacteremia in each treatment group) x 100

Time frame:
from the first administration to TOC (4 weeks after EOT)
Reported as:
Count of participants · Participants
Relapse Rate of MRSA bacteremia_PPS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Relapse Rate of MRSA bacteremia_PPS21
SecondaryClearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_FAS

* Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100

Time frame:
Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
Reported as:
Count of participants · Participants
Clearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_FAS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Day386
Day5911
Day776
Day14911
End of Treatment1214
SecondaryClearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_PPS

* Proportion of participants who confirmed MRSA negative two consecutive set in the blood culture test * Clearance Rate = (number of subjects who achieved clearance at each visit/number of subjects in each treatment group) x 100

Time frame:
Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
Reported as:
Count of participants · Participants
Clearance Rate of MRSA Bacteremia at Day 3, Day 5, Day 7, Day 14, EOT_PPS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Day355
Day588
Day765
Day14910
End of Treatment1012
SecondaryPersistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_FAS

* Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100

Time frame:
Day 3, Day 5, Day 7, Day 14
Reported as:
Count of participants · Participants
Persistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_FAS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Day3612
Day547
Day713
Day1402
SecondaryPersistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_PPS

* Proportion of participants who have positive results on blood culture tests * Persistent rate of bacteremia = (number of subjects who showing persistent bacteremia up to each visit /number of subjects in each treatment group up to each visit) x 100

Time frame:
Day 3, Day 5, Day 7, Day 14
Reported as:
Count of participants · Participants
Persistent Rate of Bacteremia at Day 3, Day 5, Day 7, Day 14_PPS
ParticipantsCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Day359
Day536
Day703
Day1402
SecondaryTime to Clearance of MRSA bacteremia_FAS

If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.

Time frame:
by EOT (up to 6 weeks)
Reported as:
Median · days
Time to Clearance of MRSA bacteremia_FAS
daysCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Time to Clearance of MRSA bacteremia_FAS7.00 (3.00 to 14.00)8.00 (4.00 to 18.00)
SecondaryTime to Clearance of MRSA bacteremia_PPS

If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.

Time frame:
by EOT (up to 6 weeks)
Reported as:
Median · days
Time to Clearance of MRSA bacteremia_PPS
daysCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Time to Clearance of MRSA bacteremia_PPS4.00 (3.00 to 14.00)7.00 (4.00 to 18.00)
Other pre-specifiedVancomycin MIC Level

Vancomycin minimum inhibitory concentration (MIC) levels

Time frame:
at Screening visit (baseline)
Reported as:
Mean · mcg/ml
Vancomycin MIC Level
mcg/mlCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Vancomycin MIC Level0.78 ± 0.2560.75 ± 0.258
Other pre-specifiedDelpazolid MIC Levels

Delpazolid minimum inhibitory concentration (MIC) level by broth microdilution (BMD)

Time frame:
Screening (Baseline), Day 14, EOT
Reported as:
Mean · mcg/ml
Delpazolid MIC Levels
mcg/mlCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
Baseline1.1 ± 0.341.1 ± 0.42
Day141.0 ± NA1.0 ± 0.00
End of Treatment1.0 ± NA—
Other pre-specifiedPharmacokinetics (PK) parameters_AUC,ss

Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (AUC,ss: Area under the concentration-time curve at steady state)

Time frame:
Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Reported as:
Mean · ng*h/mL
Pharmacokinetics (PK) parameters_AUC,ss
ng*h/mLTotalNo ESRDESRDNot Undergoing HDUndergoing HDNo HI/LCHI/LC
Pharmacokinetics (PK) parameters_AUC,ss90,855.222 ± 88,895.53883,671.053 ± 75,411.51199,065.701 ± 107,966.645112,462.317 ± 111,518.90358,444.580 ± 11,292.56059,842.551 ± 26,423.362152,880.564 ± 137,383.144
Other pre-specifiedPharmacokinetics (PK) parameters_Cmax,ss

Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmax,ss: Maximum concentration of drug at steady state)

Time frame:
Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) parameters_Cmax,ss
ng/mLTotalNo ESRDESRDNot Undergoing HDUndergoing HDNo HI/LCHI/LC
Pharmacokinetics (PK) parameters_Cmax,ss8,595.050 ± 7,229.1368,610.266 ± 5,715.0318,577.661 ± 9,156.15210,903.652 ± 8,712.9505,132.147 ± 938.6016,216.075 ± 1,624.92513,353.002 ± 11,598.454
Other pre-specifiedPharmacokinetics (PK) parameters_Cmin,ss

Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Cmin,ss: Minimum concentration of drug at steady state)

Time frame:
Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) parameters_Cmin,ss
ng/mLTotalNo ESRDESRDNot Undergoing HDUndergoing HDNo HI/LCHI/LC
Pharmacokinetics (PK) parameters_Cmin,ss6,586.689 ± 7,255.8445,541.150 ± 6,209.5277,781.590 ± 8,644.9857,955.430 ± 9,284.2444,533.576 ± 1,032.6383,992.895 ± 2,331.77911,774.277 ± 11,026.039
Other pre-specifiedPharmacokinetics (PK) parameters_Tmax,ss

Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (Tmax,ss: Time to reach Cmax at steady state)

Time frame:
Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Reported as:
Mean · h
Pharmacokinetics (PK) parameters_Tmax,ss
hTotalNo ESRDESRDNot Undergoing HDUndergoing HDNo HI/LCHI/LC
Pharmacokinetics (PK) parameters_Tmax,ss3.562 ± 1.3223.083 ± 1.5154.110 ± 0.8613.286 ± 1.5423.978 ± 0.8613.291 ± 1.4294.105 ± 0.984
Other pre-specifiedPharmacokinetics (PK) parameters_t1/2β

Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (t1/2β : Terminal elimination half-life)

Time frame:
Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Reported as:
Mean · h
Pharmacokinetics (PK) parameters_t1/2β
hTotalNo ESRDESRDNot Undergoing HDUndergoing HDNo HI/LCHI/LC
Pharmacokinetics (PK) parameters_t1/2β9,292.011 ± 28,745.8581,689.649 ± 4,369.24817,980.425 ± 41,721.54113,973.252 ± 37,076.7612,270.149 ± 3,949.333425.392 ± 572.10727,025.249 ± 47,976.785
Other pre-specifiedPharmacokinetics (PK) parameters_MRT,ss

Plasma LCB01-0371 concentration data in MRSA bacteremia patients were used to establish a pharmacokinetic model using NONMEM®. A two-compartment model, in which the Hemodialysis (HD) status and albumin as a covariate, was selected as the final model. (MRT,ss: Mean residence time at steady state)

Time frame:
Plasma samples for pharmacokinetic evaluation were collected once at each timepoint on Day 1 and between Day 3 and end of treatment (EOT), specifically at 30 minutes to 1 hour and 2 to 8 hours after administration of the investigational product.
Reported as:
Mean · h
Pharmacokinetics (PK) parameters_MRT,ss
hTotalNo ESRDESRDNot Undergoing HDUndergoing HDNo HI/LCHI/LC
Pharmacokinetics (PK) parameters_MRT,ss6,843.719 ± 20,060.0371,159.389 ± 3,024.81513,340.095 ± 28,912.8339,730.567 ± 25,868.7382,513.446 ± 4,304.084436.814 ± 654.94719,657.528 ± 33,160.057

Adverse events

Collected over From IP administration to TOC (Test of Cure, 4 weeks after EOT*), approximately 10 weeks *EOT (End of treatment): up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BID0/18 (0%)0/18 (0%)13/18 (72.2%)
Monotherapy - Vancomycin IV Plus Placebo of Delpazolid1/20 (5%)1/20 (5%)16/20 (80%)
Most frequent serious events
Most frequent serious events
EventCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
end stage renal diseaseRenal and urinary disorders0/181/20
Most frequent other events
Showing 10 of 56
Most frequent other events
EventCombination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of Delpazolid
DiarrhoeaGastrointestinal disorders5/180/20
AnaemiaBlood and lymphatic system disorders3/185/20
ConstipationGastrointestinal disorders1/183/20
PruritusSkin and subcutaneous tissue disorders1/183/20
COVID-19Infections and infestations2/180/20
HypertensionVascular disorders2/180/20
PyrexiaGeneral disorders2/181/20
Adrenal insufficiencyEndocrine disorders2/180/20
Melaena 0 [0] 2 (10.00) [2]Gastrointestinal disorders0/182/20
Urinary tract infectionInfections and infestations0/182/20

Baseline characteristics

Safety Set (SS)

Age, Categorical
Age, Categorical(Participants)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
<=18 years000
Between 18 and 65 years51015
>=65 years131023
Age, Continuous
Age, Continuous(years)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Mean69.3 ± 9.6864.5 ± 16.4766.8 ± 13.73
Sex: Female, Male
Sex: Female, Male(Participants)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Female71017
Male111021
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Count of participants——0
Childbearing potential
Childbearing potential(Participants)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Yes022
No7815
Height (cm)
Height (cm)(cm)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Mean164.15 ± 6.302161.85 ± 7.582162.94 ± 7.009
Weight (kg)
Weight (kg)(kg)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Mean64.77 ± 9.53663.59 ± 13.25664.14 ± 11.506
BMI (kg/m2)
BMI (kg/m2)(kg/m^2)Combination Therapy - Vancomycin IV Plus Delpazolid 800 mg, PO, BIDMonotherapy - Vancomycin IV Plus Placebo of DelpazolidTotal
Mean24.020 ± 3.175424.229 ± 4.673224.130 ± 3.9823

4 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Chosun University Hospital
    Gwangju, 61453, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, Korea, Republic of
  • Korea University Ansan Hospital
    Gyeonggi-do, 15355, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified individual patient data, that underlie the results in published article(s) based on data from the trial which including text, tables, figures will be presented to various stakeholders. This reported will be presented to various stakeholder during various forums or meetings. First results will be disclosed to participants, staff and our site Community Advisory Board. Thereafter we would invite several stakeholders from the community or visit their establishments to review study results. Simultaneously, the studying findings report will be sent to the various regulatory authorities, including the National Department of Health (NDoH). With NDoH and its divisions we will establish needs for further engagement and suggestions for policy or programmatic changes.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be provided 1-2 years after and up to 5 years after the publication of the article on the results of the trial.

Access criteria: IPD access will be provided for analyses of the related to the aims of research described in the protocol and for individual patient data meta analyses to researches who provide a methodologically sound proposal to lcb_pv@legochembio.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Feb 2024, 21 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2022
First posted
Feb 4, 2022
StartActual
Apr 26, 2022
Primary completionActual
Feb 21, 2024
CompletionActual
Mar 18, 2024
Results first posted
May 6, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05225558
Lead sponsor
LigaChem Biosciences, Inc.
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Apr 26, 2022
Primary completion
Feb 21, 2024
Completion
Mar 18, 2024
Results posted
May 6, 2025
Last update
May 6, 2025

Study contacts

Hongbin Kim
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delpazolid

Start the discussion